Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study

The authors aimed to evaluate the real-world effectiveness of upadacitinib in patients with Crohn's disease through a multicentre retrospective cohort study. They found that upadacitinib demonstrated good treatment persistence and significant reductions in disease activity markers, with 64% of patients achieving clinical remission at 12 weeks, although adverse events were reported in 40% of the cohort. Overall, the study suggests that upadacitinib is effective in a highly refractory patient population.